Skip to Content

Join the 'Hepatitis C' group to help and get support from people like you.

Hepatitis C News

Related terms: Hepatitis C, Chronic, Chronic Hepatitis C, Hep C

Hepatitis C Screening May Boost Opioid Treatment Success

Posted 2 days 3 hours ago by Drugs.com

FRIDAY, Oct. 20, 2017 – Opioid abuse therapy may be more effective if patients are screened for hepatitis C as part of the program, a new Canadian study says. The research found a sharp drop in opioid abuse among patients after they were told they tested positive for the hepatitis C virus (HCV). Hepatitis C causes liver disease that can lead to cirrhosis (scarring of the liver), liver cancer and liver failure, the researchers said. "Our study showed awareness of HCV infection among this particular population may motivate them to reduce their consumption and hopefully high-risk behavior," said lead investigator Dr. Hooman Farhang Zangneh, a postdoctoral research fellow at the Toronto Centre for Liver Disease at Toronto General Hospital. The primary cause of hepatitis C transmission is infected blood, which is often transmitted through needle sharing to inject drugs. The study included ... Read more

Related support groups: Suboxone, Oxycodone, Hydrocodone, Tramadol, Percocet, Methadone, OxyContin, Vicodin, Norco, Fentanyl, Opiate Dependence, Morphine, Codeine, Lortab, Opiate Withdrawal, Opana, Hepatitis C, Subutex, Dilaudid, Opana ER

Semen Harbors Wide Range of Viruses

Posted 13 Sep 2017 by Drugs.com

WEDNESDAY, Sept. 13, 2017 – Human semen provides a potential hiding place and breeding ground for a host of dangerous viruses, a new evidence review reports. The analysis of current medical literature revealed genetic evidence of 27 infectious viruses found in semen, including dread-inducing agents like Zika, Ebola, Marburg, Lassa fever and chikungunya, along with mumps, Epstein-Barr and chicken pox. "Clinicians and researchers need to consider the possibility that traditionally non-sexually transmitted viruses can persist in semen, and this therefore raises the possibility of sexual transmission," said lead researcher Alex Salam. He is a clinical researcher with the University of Oxford's epidemic diseases research group in the United Kingdom. However, the presence of viruses in semen does not mean that every virus can be sexually transmitted, the researchers noted. "Detection means ... Read more

Related support groups: Hepatitis C, HIV Infection, Herpes Simplex, Hepatitis B, Viral Infection, Exposure to Hepatitis B Virus, Mumps Polyneuropathy

Only About One-Third of Americans Use Condoms: CDC

Posted 10 Aug 2017 by Drugs.com

THURSDAY, Aug. 10, 2017 – Condoms can help prevent pregnancy and the spread of sexually transmitted diseases (STDs), but only about a third of Americans use them, a new federal report shows. "The use of condoms is a public health issue," said report author Casey Copen, a statistician at the U.S. Centers for Disease Control and Prevention's National Center for Health Statistics. "STDs can lead to long-term consequences, such as infertility," she said. "Condoms, when used consistently and correctly, reduce the risk of HIV and STDs." About 20 million new cases of STDs are diagnosed each year in the United States, the CDC said. These infections include human papillomavirus (HPV), gonorrhea, chlamydia, syphilis, hepatitis and HIV. The choice of whether to use a condom or not is influenced by a number of factors. These include: a woman's desire to get pregnant, one's experience using other ... Read more

Related support groups: Birth Control, Contraception, Plan B, Emergency Contraception, Mirena, Nexplanon, Depo-Provera, Provera, NuvaRing, Sprintec, Implanon, Ortho Tri-Cyclen, Tri-Sprintec, Hepatitis C, Microgestin Fe 1/20, Yasmin, Plan B One-Step, Loestrin 24 Fe, Ortho Evra, Lutera

FDA Approves Expanded Labeling for Epclusa (sofosbuvir/velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV

Posted 9 Aug 2017 by Drugs.com

FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 1, 2017-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Epclusa® (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV. Epclusa received regulatory approval for the treatment of adults with genotype 1-6 chronic HCV infection without cirrhosis or with compensated cirrhosis, or with decompensated cirrhosis in combination with ribavirin, in the United States on June 28, 2016. Epclusa has a boxed warning in its product label regarding the risk of hepatitis B virus (HBV) reactivation in HCV/HBV co-infected patients. See below for important safety information. “HCV co-infection re ... Read more

Related support groups: Hepatitis C, HIV Infection, Hepatitis, Epclusa, Sofosbuvir, Sofosbuvir/velpatasvir

Mavyret Approved for Hepatitis C

Posted 4 Aug 2017 by Drugs.com

FRIDAY, Aug. 4, 2017 --Mavyret (glecaprevir and pibrentasvir) has been approved by the U.S. Food and Drug Administration to treat adults with certain types of chronic hepatitis C virus (HCV). The combination drug is the first approved therapy for hepatitis C to require as few as eight weeks of treatment, the FDA said in a news release. Other therapies require treatment of 12 weeks or longer. "This approval provides a shorter treatment duration for many patients, and also a treatment option for certain patients . . . who were not successfully treated with other direct-acting antiviral treatments," said Dr. Edward Cox, director of the FDA's Office of Antimicrobial Products. HCV causes liver inflammation, potentially leading to reduced liver function or liver failure, the agency said. Symptoms and complications may include jaundice, a yellowing of the skin; bleeding; abdominal fluid ... Read more

Related support groups: Hepatitis C, Chronic Active Hepatitis, Mavyret, Glecaprevir/pibrentasvir

FDA Approves Mavyret (glecaprevir and pibrentasvir) for Hepatitis C

Posted 3 Aug 2017 by Drugs.com

August 3, 2017 – The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. Mavyret is also approved for adult patients with HCV genotype 1 infection who have been previously treated with a regimen either containing an NS5A inhibitor or an NS3/4A protease inhibitor but not both. Mavyret is the first treatment of eight weeks duration approved for all HCV genotypes 1-6 in adult patients without cirrhosis who have not been previously treated. Standard treatment length was previously 12 weeks or more. “This approval provides a shorter treatment duration for many patients, and also a treatment option for certain patients with genotype 1 i ... Read more

Related support groups: Hepatitis C, Hepatitis, Mavyret, Glecaprevir/pibrentasvir

FDA Approves Vosevi (sofosbuvir, velpatasvir and voxilaprevir) for Hepatitis C

Posted 18 Jul 2017 by Drugs.com

July 18, 2017 – The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs – sofosbuvir and velpatasvir – and a new drug, voxilaprevir. Vosevi is the first treatment approved for patients who have been previously treated with the direct-acting antiviral drug sofosbuvir or other drugs for HCV that inhibit a protein called NS5A. “Direct-acting antiviral drugs prevent the virus from multiplying and often cure HCV. Vosevi provides a treatment option for some patients who were not successfully treated with other HCV drugs in the past,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. Hepatitis C is a viral di ... Read more

Related support groups: Hepatitis C, Hepatitis, Sofosbuvir, Sofosbuvir/velpatasvir, Vosevi, Sofosbuvir/velpatasvir/voxilaprevir

Surf's Up! How to Plan for a Safe Beach Vacation

Posted 25 Jun 2017 by Drugs.com

SATURDAY, June 24, 2017 – Heading to the beach this summer? Make safety part of your vacation planning. Sun protection belongs at the top of your packing list. Must-haves include sunscreen, sunglasses, protective clothing and a hat, the U.S. Food and Drug Administration says. Here are some of the agency's other recommendations: Don't use tanning beds to pre-tan before a beach vacation. The lamps emit harmful ultraviolet rays that can damage your skin. Also, be aware that spray tans and bronzers do not protect against UV rays. Make a list of medications you need to take, and get enough to last the trip. Keep your medicines with you when traveling. Also, carry a detailed list of what medicines you take and have your health care provider's contact information in case you need medical care while you're away. If you wear contact lenses, pack enough for the entire vacation. Don't forget to ... Read more

Related support groups: Eye Conditions, Hepatitis C, HIV Infection, Sunburn, Sunscreen, Prevention of Sunburn, Visual Defect/Disturbance, Coppertone, Deeptan

U.S. Liver Cancer Deaths Have Doubled Since 1980s: Study

Posted 7 Jun 2017 by Drugs.com

WEDNESDAY, June 7, 2017 – Liver cancer is the fastest-growing cause of cancer deaths in the United States, a new study reports. Liver cancer cases have been on the rise since the mid-1970s, a trend expected to continue through at least 2030. Death rates from the disease have doubled since the mid-1980s – the fastest increase of any cancer, according to the American Cancer Society, which conducted the study. About 41,000 new cases of liver cancer and 29,000 deaths from the disease are projected in the United States this year, the cancer society said. Liver cancer is now the fifth-leading cause of cancer death in men and the eighth-leading cause in women. About 1 percent of people will be diagnosed with the disease during their lives. Only 1 in 5 survives five years after diagnosis, said the researchers led by Dr. Farhad Islami. Islami is strategic director of cancer surveillance ... Read more

Related support groups: Hepatitis C, Liver Cirrhosis, Liver and Pancreatic Disease, Hepatitis B Adult Vaccine, Twinrix, Hepatic Tumor, Vaccination and Prophlaxis, Engerix-B, Hepatitis A Adult Vaccine/hepatitis B Adult Vaccine

New Combo Pill Offers Hope to Hepatitis C Patients Who Fail Other Treatment

Posted 1 Jun 2017 by Drugs.com

WEDNESDAY, May 31, 2017 – A pill that contains three powerful antiviral drugs might offer a cure for many hepatitis C patients who have failed other treatments, researchers report. The pill – which contains the antiviral drugs sofosbuvir (Sovaldi), velpatasvir and voxilaprevir – was nearly 100 percent effective in curing hepatitis C in patients whose disease returned after treatment with other antiviral drugs, the researchers said. "Currently, we have very good treatments for hepatitis C, and we are able to achieve a cure in over 90 percent of patients. So globally, although only a few patients relapse, it still is a significant number," said lead researcher Dr. Marc Bourliere, from the Hospital Saint Joseph in Marseilles, France. This new pill is being developed as a rescue treatment for patients who have failed other therapy, he said. When it was used as an initial treatment in ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Epclusa, Sofosbuvir, Ledipasvir/sofosbuvir, Sofosbuvir/velpatasvir

New Hepatitis C Infections Hit 15-Year High: CDC

Posted 14 May 2017 by Drugs.com

FRIDAY, May 12, 2017 – Reports of new hepatitis C infections in the United States nearly tripled over five years, reaching a 15-year high, federal government data show. The highest number of new infections were reported among 20- to 29-year-olds. Many stemmed from the growing use of injected drugs linked to the current opioid epidemic, officials said. The number of reported cases rose from 850 in 2010 to 2,436 in 2015, according to the U.S. Centers for Disease Control and Prevention. But nearly half of people who have the liver infection don't know it, so most new cases are never reported. The CDC estimated there were actually about 34,000 new hepatitis C infections nationwide in 2015. "We must reach the hardest-hit communities with a range of prevention and treatment services that can diagnose people with hepatitis C and link them to treatment. This wide range of services can also ... Read more

Related support groups: Hepatitis C, Viral Infection, Liver and Pancreatic Disease

A 2nd Life for Risky Kidney Transplants?

Posted 11 May 2017 by Drugs.com

THURSDAY, May 11, 2017 – Philadelphia doctors say they cleared hepatitis C infections in 10 patients who received kidneys from deceased donors who had the virus. The findings suggest hundreds more of these transplants could take place each year, thus reducing wait time for a lifesaving kidney, the doctors said. "Our pilot data demonstrate the ability to cure the contracted virus following transplantation in this patient population," said the study co-leader, Dr. David Goldberg. "If future studies are successful, this may be a viable option for patients who may otherwise never see a transplant," added Goldberg, an assistant professor of medicine and epidemiology at the University of Pennsylvania School of Medicine. In the United States, more than 97,000 people need a kidney transplant. Many must wait for five or more years, the researchers said in background notes. Kidneys from donors ... Read more

Related support groups: Hepatitis C, Renal Transplant, Organ Transplant, Kidney Transplant

High Rates of Hepatitis C in Pregnancy Mirror Opioid Epidemic: CDC

Posted 11 May 2017 by Drugs.com

THURSDAY, May 11, 2017 – Chalk up another potential consequence of the U.S. opioid epidemic: The prevalence of hepatitis C infections among pregnant women nearly doubled between 2009 and 2014, U.S. health officials report. Hepatitis C – which is caused most often by injection drug use – rose 89 percent nationwide among pregnant women. Increases were most notable in West Virginia and rural counties in Tennessee, areas hard-hit by the heroin and prescription painkiller epidemic, the U.S. Centers for Disease Control and Prevention reported. Nationwide, 35 infants a day were exposed to the contagious liver disease, on average, study authors said. "We have seen a dramatic increase in opioid use in pregnancy and in the number of infants having drug withdrawal," said report author Dr. Stephen Patrick, of Vanderbilt University Medical Center in Nashville. "Taken together, this suggests that ... Read more

Related support groups: Suboxone, Oxycodone, Hydrocodone, Tramadol, Percocet, Methadone, OxyContin, Vicodin, Norco, Fentanyl, Opiate Dependence, Morphine, Codeine, Lortab, Opiate Withdrawal, Opana, Hepatitis C, Subutex, Dilaudid, Opana ER

New Hepatitis C Treatments More Effective, Tolerable: FDA

Posted 11 May 2017 by Drugs.com

THURSDAY, May 11, 2017 – Hepatitis C can be cured in about three months, allowing people with the viral disease to live longer, healthier lives, the U.S. Food and Drug Administration (FDA) says. Drugs used to clear the virus from the body are not only more effective than they once were but also more tolerable for patients, according to Dr. Jeffrey Murray, an internist at the FDA who specializes in infectious diseases. Hepatitis is inflammation of the liver that is caused by different viruses. In the United States, hepatitis C is the most common chronic bloodborne infection. Avoiding risky behaviors, such as sharing drug needles, can help prevent the spread of the disease, but there is no vaccine for hepatitis C. Hepatitis is often a silent disease. Many people are unaware they are infected for years and learn about their infection only after they have developed serious liver disease or ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Epclusa, Zepatier, Sofosbuvir, Ledipasvir/sofosbuvir, Sofosbuvir/velpatasvir

FDA Approves Sovaldi (sofosbuvir) for Chronic Hepatitis C Infection in Pediatric Patients 12 Years and Older

Posted 8 Apr 2017 by Drugs.com

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 7, 2017-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental indications for Sovaldi (sofosbuvir 400 mg) tablets for the treatment of chronic hepatitis C virus (HCV) infection in adolescents without cirrhosis or with compensated cirrhosis, 12 years of age and older, or weighing at least 35kg. Sovaldi was approved for pediatric patients with genotype 2 or 3 chronic HCV infection, in combination with ribavirin. There are an estimated 23,000-46,000 pediatric HCV patients in the United States, most of whom were infected with the virus at birth. Sovaldi has a boxed warning in their respective product labels regarding the risk of hepatitis B virus reactivation in HCV/HBV co-infected patients. See below for important safety information. Sovaldi for Pediatric Patients The ... Read more

Related support groups: Hepatitis C, Sovaldi, Sofosbuvir

Page 1 2 3 ... Next

Ask a Question

Further Information

Related Condition Support Groups

Infectious Hepatitis

Related Drug Support Groups

Harvoni, Sovaldi, ribavirin, Epclusa, Incivek, Pegasys, Zepatier, Victrelis, sofosbuvir, view more... PegIntron, Daklinza, Viekira Pak, Ribasphere, Copegus, interferon alfa-2b, telaprevir, ledipasvir / sofosbuvir, boceprevir, Rebetol, interferon alfa-2a, interferon alfa-2b / ribavirin, Mavyret, Rebetron, Vosevi, peginterferon alfa-2b, daclatasvir, Olysio, Intron A, RibaPak, sofosbuvir / velpatasvir, ombitasvir / paritaprevir / ritonavir, Roferon-A, simeprevir, Technivie, peginterferon alfa-2a, Viekira XR, RibaTab, dasabuvir / ombitasvir / paritaprevir / ritonavir, elbasvir / grazoprevir, Moderiba, interferon alfacon-1, sofosbuvir / velpatasvir / voxilaprevir, glecaprevir / pibrentasvir, Infergen